US Bancorp DE Sells 220 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

US Bancorp DE cut its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 0.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,410 shares of the company’s stock after selling 220 shares during the period. US Bancorp DE’s holdings in Henry Schein were worth $2,581,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Cromwell Holdings LLC increased its stake in shares of Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares during the period. Summit Securities Group LLC acquired a new stake in Henry Schein during the second quarter worth about $31,000. Beach Investment Counsel Inc. PA acquired a new stake in Henry Schein during the second quarter worth about $37,000. Blue Trust Inc. grew its position in Henry Schein by 104.2% during the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in Henry Schein by 282.1% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,490 shares of the company’s stock worth $109,000 after buying an additional 1,100 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Stock Down 4.6 %

Shares of HSIC opened at $68.99 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90. The business’s 50 day simple moving average is $70.60 and its 200-day simple moving average is $69.78. Henry Schein, Inc. has a one year low of $62.05 and a one year high of $82.63. The company has a market capitalization of $8.74 billion, a P/E ratio of 25.55, a PEG ratio of 2.02 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The firm had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter in the previous year, the company posted $1.31 EPS. Henry Schein’s revenue was up .0% on a year-over-year basis. As a group, sell-side analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.14% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HSIC shares. Robert W. Baird decreased their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Evercore ISI lifted their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Finally, UBS Group decreased their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $77.50.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.